启迪药业(000590) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥76,738,641.22, representing a 26.86% increase compared to ¥60,492,169.00 in the same period last year[8] - Net profit attributable to shareholders was ¥20,462,099.92, a significant increase of 130.40% from ¥8,881,121.45 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥15,555,451.00, up 88.94% from ¥8,232,884.55 in the previous year[8] - Basic earnings per share were ¥0.0854, a 130.19% increase compared to ¥0.0371 in the previous year[8] - Total operating revenue for Q1 2021 was CNY 76,738,641.22, compared to CNY 60,492,169.00 in the previous period, indicating a growth of approximately 26.5%[37] - Total operating income for Q1 2021 was 21,543,087.21, an increase from 9,315,201.57 in the same period last year, representing a growth of approximately 131.5%[39] - Net profit for Q1 2021 reached 20,462,099.92, compared to 8,881,121.45 in Q1 2020, marking an increase of about 130.5%[39] - The total profit for Q1 2021 was 21,464,647.42, compared to 9,381,121.45 in Q1 2020, reflecting an increase of about 128.5%[39] Cash Flow - The net cash flow from operating activities reached ¥3,802,179.07, marking a 90.24% increase from ¥1,998,622.54 in the same period last year[8] - The net cash flow from operating activities for Q1 2021 was ¥3,802,179.07, an increase of 90.4% compared to ¥1,998,622.54 in Q1 2020[47] - Total cash inflow from operating activities was ¥89,328,531.40, while cash outflow was ¥85,526,352.33, resulting in a net cash inflow of ¥3,802,179.07[47] - Cash flow from operating activities was 80,835,182.44 in Q1 2021, compared to 75,978,266.31 in the previous year, showing an increase of about 6.5%[46] - The cash flow from investment activities showed a net outflow of ¥49,301,913.95, compared to a net outflow of ¥13,986,001.76 in the previous year, indicating increased investment expenditures[47] - The net cash flow from financing activities was negative at ¥50,000.00, indicating cash outflow for dividend payments[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥920,837,438.72, reflecting a 3.21% increase from ¥892,157,636.28 at the end of the previous year[8] - Total liabilities rose to CNY 255,491,873.41 from CNY 247,274,170.89, marking an increase of approximately 3.5%[31] - The company's cash and cash equivalents amounted to CNY 130,222,017.31, up from CNY 126,099,948.73, showing a slight increase of about 1.7%[32] - The total non-current assets were CNY 392,537,833.41, compared to CNY 383,541,799.65 in the previous period, representing an increase of approximately 2.5%[32] - The company's total equity reached CNY 665,345,565.31, up from CNY 644,883,465.39, indicating a growth of about 3.2%[32] - The current liabilities totaled CNY 163,408,757.12, slightly increasing from CNY 161,016,210.38, which is an increase of about 1.5%[31] - The company’s long-term liabilities increased to CNY 92,083,116.29 from CNY 86,257,960.51, reflecting a growth of approximately 6.5%[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,074[11] - The largest shareholder, Tsinghua Tongfang Co., Ltd., held 29.41% of the shares, totaling 70,432,904 shares[11] Government Subsidies and Other Income - The company received government subsidies amounting to ¥5,042,933.55 during the reporting period[9] - The company reported a 658.18% increase in other income to CNY 5,066,598.01, primarily from government subsidies received[15] - The company recorded other income of 5,066,598.01 in Q1 2021, up from 668,261.09 in Q1 2020, indicating a growth of approximately 658.5%[39] Operational Developments - The company completed the technical transformation project for producing 250 million bottles of health essence liquid, which has begun formal production[21] - The company has a remaining balance of CNY 142,743,864.14 in its fundraising special account as of March 31, 2021[21] - The company has no overdue or unfulfilled commitments from major shareholders or related parties during the reporting period[24] - The company has no significant securities or derivative investments during the reporting period[19][20] Financial Standards and Reporting - The first quarter report for 2021 was not audited[59] - The company implemented the new leasing standard from January 1, 2021, resulting in an increase of right-of-use assets and lease liabilities by ¥2,616,082.59 each[56]